A Chicagoland medical company that makes a device to make it easier for doctors to see in surgery said it's raised $15 in a Series B funding round.Employees formed a limited liability company that contributed $4 million to the funding. Read More →
Augmedics’ xvision Spine System has been successfully used for the first time in a spinal fusion surgery in the United States. The system was used in a spinal surgery procedure by Johns Hopkins University surgeons. Augmedics’ xvision Spine System has been successfully used for the first time in a spinal fusion surgery in the United States. The system was used in a spinal surgery procedure by Johns Hopkins University surgeons. Read More →
Augmedics announced today that it won FDA 510(k) clearance for and initiated the U.S. launch of its Xvision Spine augmented reality guidance system to be used in surgery. The company is touting Xvision Spine as the first AR guidance system to... Read More →
Rapid advances in the development of medical devices in the 21st century are contributing to healthier lives, but bring with them a new challenge: teaching clinicians how to use these often-complicated technologies. Teaching them poorly, or failing to do it... Read More →
Augmedics’ Xvision headset superimposes CT scans and other medical imaging over a patient’s body during an operation. Augmedics’ surgical “X-ray specs” are really an augmented-reality headset that superimposes CT scans and other images over a patient’s body, helping surgeons map... Read More →
The North American Spine Society (NASS) 2018 event that took place in September seemed quite similar to the ones I’ve attended during previous years. The overwhelming focus (on the expo floor anyway) was on technologies and solutions involved in spinal... Read More →
Augmedics, a developer of an augmented-reality (AR) surgical visualization system, has secured $8.3 million in Series A funding. Led by Davos, Switzerland-based AO Invest, which is fully funded by the non-profit AO Foundation, as well as Israeli Innovation Authority, Terra Venture Partners and other undisclosed investors. Augmedics will use the proceeds to complete research and development as well as pre-clinical and clinical trials of its ViZOR System, establish strategic distribution partnerships, and seek 510(k) clearance for The ViZOR from the US. Food and Drug Administration.